Idursulfase
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| ATC code | A16AB09 (WHO) |
| Identifiers | |
| CAS Number |
50936-59-9  |
| DrugBank |
DB01271 |
| ChemSpider | none |
| UNII |
5W8JGG2651 |
| KEGG |
D04499 |
| ChEMBL |
CHEMBL1201826  |
| (what is this?) (verify) | |
Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4]
References
- ↑ Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
- ↑ "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
- ↑ Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
- ↑ , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
External links
- idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)
This article is issued from Wikipedia - version of the 11/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.